Das Medizinportal



Aktuelle Aspekte in der Behandlung von Hodentumoren (S. 18–22)

Maximilian P. Brandt, Robert Dotzauer, Thomas Höfner


  1. Boccellino M, Vanacore D, Zappavigna S, Cavaliere C, Rossetti S, D'Aniello C, et al. Testicular cancer from diagnosis to epigenetic factors. Oncotarget 2017; 8(61): 104654–63
  2. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol 2011; 60(2): 374–9
  3. Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. W J Urol 2004; 22(1): 2–14
  4. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. Journal of the National Cancer Institute 2005; 97(14): 1056–66
  5. Lerro CC, McGlynn KA, Cook MB. A systematic review and meta-analysis of the relationship between body size and testicular cancer. British journal of cancer 2010; 103(9): 1467–74
  6. Ghazarian AA, Kelly SP, Altekruse SF, Rosenberg PS, McGlynn KA. Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. Cancer 2017; 123(12): 2320–8
  7. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group.  JUrol 1998; 160(4): 1353–7
  8. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. AnlsOncol 2005; 16(6): 863–8
  9. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002; 42(6): 553–62; discussion 62–3
  10. Moul JW. Timely diagnosis of testicular cancer. Urol Clin North Am. 2007;34(2):109-17; abstract vii.
  11. Kim W, Rosen MA, Langer JE, Banner MP, Siegelman ES, Ramchandani P. US MR imaging correlation in pathologic conditions of the scrotum. Radiographics  2007; 27(5): 1239–53
  12. Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, et al. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. Eur Urol 2017; 71(2): 213–20
  13. Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Brit J Cancer 2014; 110(1): 256–63
  14. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29(8): 957–62
  15. Tandstad T, Stahl O, Dahl O, Haugnes HS, Hakansson U, Karlsdottir A, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 2016; 27(7): 1299–304
  16. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20(22): 4448–52
  17. Aparicio J, Maroto P, Garcia del Muro X, Sanchez-Munoz A, Guma J, Margeli M, et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 2014; 25(11): 2173–8
  18. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007; 64(3): 182–97
  19. Hallemeier CL, Pisansky TM, Davis BJ, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma – the Mayo Clinic experience. Urol Oncol 2013; 31(8): 1832–8
  20. Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Fare E, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 2015; 26(4): 657–68
  21. Daugaard G, Gundgaard MG, Mortensen MS, Agerbaek M, Holm NV, Rorth M, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 2014; 32(34): 3817–23
  22. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 21(8): 1505–12
  23. Tandstad T, Stahl O, Hakansson U, Dahl O, Haugnes HS, Klepp OH, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 2014; 25(11): 2167–72
  24. Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU intern 2010; 106(6): 779–85
  25. Thibault C, Fizazi K, Barrios D, Massard C, Albiges L, Baumert H, et al. Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. Eur J Cancer 2014; 50(7): 1284–90
  26. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol 2015; 68(6): 1054–68
  27. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. JClin Oncol 1996; 14(2): 454–60
  28. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007; 25(9): 1033–7
  29. Ravi P, Gray KP, O'Donnell EK, Sweeney CJ. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol 2014; 25(2): 331–8
  30. Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28(4): 531–6
  31. Hemminki K, Liu H, Sundquist J. Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol 2010; 21(7): 1546–51
  32. Piketty AC, Flechon A, Laplanche A, Nouyrigat E, Droz JP, Theodore C, et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Brit J Cancer 2005; 93(8): 909–14
  33. Haugnes HS, Aass N, Fossa SD, Dahl O, Brydoy M, Aasebo U, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27(17): 2779–86


Einfluss fertilitätsprotektiver Maßnahmen auf die Psyche junger Krebspatientinnen (S. 40–43)
A. Doster, S. Ditz, A. Germeyer

  1. Angarita AM, Johnson CA, Fader AN, Christianson MS. Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer. Front Oncol. 2016; 6: 102
  2. von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schuring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod Biomed Online. 2015; 31(5): 605– 12
  3. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(18): 2917– 31
  4. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010; 53(4): 727– 39
  5. Benedict C, Thom B, Kelvin JF. Fertility preservation and cancer: challenges for adolescent and young adult patients. Curr Opin Support Palliat Care. 2016; 10(1): 87– 94http://www.icd-code.de/suche/ops/code/8-982.html?sp=S8-982
  6. Su HC, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014; 120(23): 3691– 8
  7. Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. European journal of cancer. 2017; 87: 58– 64http://www.icd-code.de/ops/code/8-98h.html
  8. Reh AE, Lu L, Weinerman R, Grifo J, Krey L, Noyes N. Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: results of a registry of female cancer patients at 2 years. J Assist Reprod Genet. 2011; 28(7): 635– 41
  9. Bradford A, Woodard TL. Novel Psychological Intervention for Decision Support in Women Considering Fertility Preservation Before Cancer Treatment. J Adolesc Young Adult Oncol. 2017; 6(2): 348– 52
  10. Treves R, Grynberg M, Parco S, Finet A, Poulain M, Fanchin R. Female fertility preservation in cancer patients: an instrumental tool for the envisioning a postdisease life. Future Oncol. 2014; 10(6): 969– 74
  11. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(20): 4174– 83
  12. Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014; 32(11): 1151– 6
  13. Hershberger PE, Finnegan L, Pierce PF, Scoccia B. The decision-making process of young adult women with cancer who considered fertility cryopreservation. J Obstet Gynecol Neonatal Nurs. 2013; 42(1): 59– 69
  14. von Wolff M, Giesecke D, Germeyer A, Lawrenz B, Henes M, Nawroth F, et al. Characteristics and attitudes of women in relation to chosen fertility preservation techniques: a prospective, multicenter questionnaire-based study with 144 participants. European journal of obstetrics, gynecology, and reproductive biology. 2016; 201: 12– 7
  15. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Jr., Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016; 14:1
  16. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(19):2500– 10
  17. www.awmf.org/uploads/tx_szleitlinien/015-082l_S2k_Fertilitaetserhaltung-bei-onkologischen-Therapien_2017-12.pdf
  18. fertiprotekt.com
  19. Jadoul P, Guilmain A, Squifflet J, Luyckx M, Votino R, Wyns C, et al. Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Human reproduction 2017; 32(5): 1046– 54
  20. von Wolff M, Germeyer A, Liebenthron J, Korell M, Nawroth F. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques. Archives of gynecology and obstetrics. 2018; 297(1): 257– 67
  21. Tschudin S, Bunting L, Abraham J, Gallop-Evans E, Fiander A, Boivin J. Correlates of fertility issues in an internet survey of cancer survivors. J Psychosom Obstet Gynaecol. 2010; 31(3): 150– 7
  22. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012; 118(6): 1710– 7
  23. Geue K, Richter D, Schmidt R, Sender A, Siedentopf F, Brahler E, et al. The desire for children and fertility issues among young German cancer survivors. J Adolesc Health. 2014; 54(5): 527– 35
  24. Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27(35): 5952– 7
  25. Quinn GP, Vadaparampil ST, Jacobsen PB, Knapp C, Keefe DL, Bell GE, et al. Frozen hope: fertility preservation for women with cancer. J Midwifery Womens Health. 2010; 55(2): 175– 80
  26. Lawson AK, Klock SC, Pavone ME, Hirshfeld-Cytron J, Smith KN, Kazer RR. Prospective study of depression and anxiety in female fertility preservation and infertility patients. Fertility and sterility. 2014; 102(5): 1377– 84
  27. Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It's now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(13): 1670– 7
  28. Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertility and sterility. 2010; 94(1): 149– 55
  29. Lawson AK, Klock SC, Pavone ME, Hirshfeld-Cytron J, Smith KN, Kazer RR. Psychological Counseling of Female Fertility Preservation Patients. J Psychosoc Oncol. 2015; 33(4): 333– 53
  30. Hill KA, Nadler T, Mandel R, Burlein-Hall S, Librach C, Glass K, et al. Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation. Clin Breast Cancer. 2012; 12(2): 127– 32
  31. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Making. 2003; 23(4): 281– 92
  32. Lee CN, Belkora J, Chang Y, Moy B, Partridge A, Sepucha K. Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg 2011; 127(1): 18– 26
  33. Deshpande NA, Braun IM, Meyer FL. Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: A systematic review. Cancer. 2015; 121(22): 3938– 47
  34. Benedict C, Thom B, D NF, Diotallevi D, E MP, N JR, et al. Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation. Cancer. 2016; 122(13): 2101– 9
  35. Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Human reproduction. 2017; 32(10): 2123– 9
  36. Melo C, Fonseca A, Moura-Ramos M, Almeida-Santos T, Canavarro MC. Female cancer patients' perceptions of the fertility preservation decision-making process: An exploratory prospective study. J Psychosoc Oncol 2018: 1– 18
  37. Garvelink MM, ter Kuile MM, Bakker RM, Geense WJ, Jenninga E, Louwe LA, et al. Women's experiences with information provision and deciding about fertility preservation in the Netherlands: 'satisfaction in general, but unmet needs'. Health Expect. 2015; 18(5): 956– 68


Urologische Tumoren: Immunonkologische Therapie etabliert sich bei GU-Tumoren (S. 56–57)

  1. Fachinformation Opdivo®, aktueller Stand
  2. Bristol-Myers Squibb, data on file
  3. Krebs in Deutschland für 2013/2014. 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2017
  4. Motzer RJ et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–1813
  5. Sharma P et al.: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18: 312–322
  6. uroweb.org/guideline/renal-cell-carcinoma
  7. www.esmo.org/guiedelines/genitourinary-cancers/renal-cell-carcinoma
  8. www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom
  9. www.onkopedia.com/de/onkopedia/guidelines/nierenzellkarzinom-hypernephrom
  10. Sharma P et al.: Three-year efficacy and safety update from the phase III checkMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma. 16th international kidney cancer symposium 2017
  11. Bedke J et al. CheckMate 275 – Phase-II-Studie: Update zur Wirksamkeit einer Nivolumab-Monotherapie bei Patienten mit einem metastasierten oder inoperablen Urothelkarzinom nach platinhaltiger Vortherapie. DGHO 2017, Vortrag V421
  12. Sharma P et al. Nivolumab monotherapy in patients with advanced, platinum-resistant urothelial carcinoma: efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. AACR 2018, Abstract CT178
  13. Domingo-Domenech J et al.: Development of target specific agents for bladder cancer. Exp Rev Prec Med Drug Devel 2016; 1: 361–368